dolutegravir sodium; rilpivirine hydrochloride · Viiv Hlthcare · NDA 210192
Juluca
Earliest generic entry, as listed
5 Sep 2038
Blocked by patent: US 12011506.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12011506 | product | 5 Sep 2038 |
| US 10426780 | substance, product, use U-257 | 24 Jan 2031 |
| US 9242986 | — | 8 Jun 2030 |
| US 9242986 | substance, product | 8 Dec 2029 |
| US 8129385 | — | 5 Apr 2028 |
| US 8129385 | substance, product | 5 Oct 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210192 · 001 · RLD | tablet, oral | EQ 50MG BASE;EQ 25MG BASE | 5 Sep 2038 |